PDS Biotechnology Corporation (PDSB) is heading in the right direction with an average volume of $892.38K

PDS Biotechnology Corporation (NASDAQ: PDSB) started the day on Wednesday, with a price increase of 7.76% at $3.61, before settling in for the price of $3.35 at the close. Taking a more long-term approach, PDSB posted a 52-week range of $2.59-$10.27.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 42.97%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.83%. This publicly-traded company’s shares outstanding now amounts to $36.68 million, simultaneously with a float of $34.89 million. The organization now has a market capitalization sitting at $132.41 million. At the time of writing, stock’s 50-day Moving Average stood at $4.31, while the 200-day Moving Average is $4.98.

PDS Biotechnology Corporation (PDSB) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. PDS Biotechnology Corporation’s current insider ownership accounts for 4.89%, in contrast to 22.45% institutional ownership.

PDS Biotechnology Corporation (PDSB) Earnings and Revenue Records

In the latest quarterly report released, which was put into the public domain on 12/31/2023, the organization reported -0.32 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -0.31) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.

PDS Biotechnology Corporation’s EPS decrease for this current 12-month fiscal period is -6.83% and is forecasted to reach -1.61 in the upcoming year.

PDS Biotechnology Corporation (NASDAQ: PDSB) Trading Performance Indicators

Let’s observe the current performance indicators for PDS Biotechnology Corporation (PDSB). It’s Quick Ratio in the last reported quarter now stands at 4.33. The Stock has managed to achieve an average true range (ATR) of 0.30.

In the same vein, PDSB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.39, a figure that is expected to reach -0.37 in the next quarter, and analysts are predicting that it will be -1.61 at the market close of one year from today.

Technical Analysis of PDS Biotechnology Corporation (PDSB)

If we take a close look at the recent performances of PDS Biotechnology Corporation (NASDAQ: PDSB), its last 5-days Average volume was 0.44 million that shows plunge from its year to date volume of 0.85 million. During the previous 9 days, stock’s Stochastic %D was recorded 83.56% While, its Average True Range was 0.28.

Raw Stochastic average of PDS Biotechnology Corporation (PDSB) in the period of the previous 100 days is set at 24.94%, which indicates a major fall in contrast to 82.93% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 102.36% that was higher than 82.92% volatility it exhibited in the past 100-days period.